COSM Key Statistics, Chart & Performance
The current stock price of COSM is 0.5 USD. In the past month the price decreased by -26.73%. In the past year, price decreased by -35.41%.
COSM Latest News, Press Relases and Analysis
COSM Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| MCK | MCKESSON CORP | 22.35 | 100.06B | ||
| COR | CENCORA INC | 21.07 | 65.31B | ||
| CAH | CARDINAL HEALTH INC | 22.31 | 47.24B | ||
| HSIC | HENRY SCHEIN INC | 15.14 | 8.59B | ||
| AHCO | ADAPTHEALTH CORP | 29.25 | 1.27B | ||
| OMI | OWENS & MINOR INC | 1.95 | 194.92M | ||
| WGRX | WELLGISTICS HEALTH INC | N/A | 52.55M |
Related stock screener links
About COSM
Company Profile
Cosmos Health, Inc. is a pharmaceutical company, which engages in the importation, exportation, distribution, and sale of pharmaceutical products. The firm owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life, Mediterranation, bio-bebe, C-Sept and C-Scrub. Through its subsidiary Cana Laboratories S.A., it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. The company also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and over-the-counter (OTC) medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the United Kingdom. The company also has research and development (R&D) partnerships targeting health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of patented nutraceuticals, specialized root extracts, proprietary complex generics, and OTC products.
Company Info
COSMOS HEALTH INC
5 Agiou Georgiou, Pilea
Thessaloniki ILLINOIS GR
Employees: 149
Phone: 303125363102
COSMOS HEALTH INC / COSM FAQ
Can you describe the business of COSMOS HEALTH INC?
Cosmos Health, Inc. is a pharmaceutical company, which engages in the importation, exportation, distribution, and sale of pharmaceutical products. The firm owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life, Mediterranation, bio-bebe, C-Sept and C-Scrub. Through its subsidiary Cana Laboratories S.A., it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. The company also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and over-the-counter (OTC) medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the United Kingdom. The company also has research and development (R&D) partnerships targeting health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of patented nutraceuticals, specialized root extracts, proprietary complex generics, and OTC products.
What is the current price of COSM stock?
The current stock price of COSM is 0.5 USD. The price increased by 2.04% in the last trading session.
What is the dividend status of COSMOS HEALTH INC?
COSM does not pay a dividend.
How is the ChartMill rating for COSMOS HEALTH INC?
COSM has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
What is the expected growth for COSM stock?
The Revenue of COSMOS HEALTH INC (COSM) is expected to grow by 25% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the market cap for COSMOS HEALTH INC?
COSMOS HEALTH INC (COSM) has a market capitalization of 17.46M USD. This makes COSM a Nano Cap stock.
COSM Technical Analysis
COSM Financial Highlights
Over the last trailing twelve months COSM reported a non-GAAP Earnings per Share(EPS) of -0.71. The EPS increased by 68.03% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -26.68% | ||
| ROE | -80.15% | ||
| Debt/Equity | 0.55 |
COSM Forecast & Estimates
For the next year, analysts expect an EPS growth of 101.28% and a revenue growth 25% for COSM